Latest Alimera Sciences (ALIM) Headlines Alimer
Post# of 51
Posted On: 03/13/2014 5:00:38 AM
Latest Alimera Sciences (ALIM) Headlines
Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference
PR Newswire - Fri Feb 28, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:00 A.M. ET in Boston, MA.
Alimera Sciences Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:07PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2013 Financial Results
PR Newswire - Thu Feb 20, 3:05PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Thursday, February 27, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET.
Strength Seen in Retrophin (RTRX): Stock Soars 49.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:04AM CST
Retrophin, Inc. was a big mover last session, as the company saw its shares rise by nearly 50% on the day.
Alimera Sciences To Present At Citi 2014 Global Healthcare Conference
PR Newswire - Thu Feb 13, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Citi 2014 Global Healthcare Conference on Tuesday, February 25, 2014 at 1:50 P.M. ET in New York, NY.
Alimera announces acceptance of ILUVIEN for NHS Scotland
M2 - Tue Feb 11, 7:22AM CST
US-based Alimera Sciences Inc (Nasdaq:ALIM), a biopharmaceutical company that specialises in the research, development and commercialisation of prescription ophthalmic pharmaceuticals, announced on Monday the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for restricted use within the National Health Service (NHS) Scotland.
Scottish Medicines Consortium Accepts ILUVIEN(R) For National Health Service Scotland
PR Newswire Europe - Mon Feb 10, 8:03AM CST
-- SMC advice follows positive NICE final guidance issued in November 2013
Scottish Medicines Consortium Accepts ILUVIEN® For National Health Service Scotland
PR Newswire - Mon Feb 10, 8:01AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Scottish Medicines Consortium (SMC), after completing its assessment and review of a simple patient access scheme, has accepted ILUVIEN® for restricted use within the National Health Service (NHS) Scotland.
8-K: ALIMERA SCIENCES INC
Edgar Online - Tue Feb 04, 12:47AM CST
ALIM-2014PIPE-Closing8-KDRAFT
Alimera Sciences Closes $37.5 Million Private Placement
PR Newswire - Mon Feb 03, 7:20AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it closed its previously announced private placement of common stock on January 31, 2014. Gross proceeds from the offering were approximately $37.5 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.
Alimera Sciences signs purchase agreement with investors for USD37.5m private placement
M2 - Wed Jan 29, 5:07AM CST
Biopharmaceutical company Alimera Sciences Inc (Nasdaq:ALIM) announced on Tuesday that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately USD37.5m of its common stock in a private placement.
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why AK Steel, Idenix Pharmaceuticals, and Alimera Sciences Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 28, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The three-day losing streak for the broad-based S&P 500 ...
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Tuesday
Synthetic Biologics (SYN) Slumps: Stock Tanks 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:38AM CST
Synthetic Biologics shares fell by over 11%. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future.
Alimera Sciences Announces $37.5 Million Private Placement
PR Newswire - Tue Jan 28, 5:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately $37.5 million of its common stock in a private placement. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 23, 1:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
Great Southern Bancorp, Inc. Reports Preliminary Fourth Quarter and Annual Earnings of $0.62 and $2.42 Per Diluted Common Share, Respectively
PR Newswire - Thu Jan 23, 6:00AM CST
-- Asset Quality: Non-performing assets and potential problem loans, excluding those covered by FDIC loss sharing agreements, totaled $89.3 million at December 31, 2013, a decrease of $32.8 million from December 31, 2012, and a decrease of $8.5 million from September 30, 2013. Non-performing assets, excluding FDIC-covered non-performing assets, at December 31, 2013, were $62.3 million, a decrease of $10.3 million from $72.6 million at December 31, 2012, and a decrease of $887,000 from $63.2 million at September 30, 2013. Non-performing assets were 1.75% of total assets at December 31, 2013, compared to 1.84% at December 31, 2012, and 1.75% at September 30, 2013. Net charge-offs were $2.2 million for the three months ended December 31, 2013, compared to $3.4 million for the three months ended September 30, 2013, and $7.4 million for the three months ended December 31, 2012.
Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference
PR Newswire - Fri Feb 28, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:00 A.M. ET in Boston, MA.
Alimera Sciences Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:07PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2013 Financial Results
PR Newswire - Thu Feb 20, 3:05PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Thursday, February 27, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET.
Strength Seen in Retrophin (RTRX): Stock Soars 49.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:04AM CST
Retrophin, Inc. was a big mover last session, as the company saw its shares rise by nearly 50% on the day.
Alimera Sciences To Present At Citi 2014 Global Healthcare Conference
PR Newswire - Thu Feb 13, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Citi 2014 Global Healthcare Conference on Tuesday, February 25, 2014 at 1:50 P.M. ET in New York, NY.
Alimera announces acceptance of ILUVIEN for NHS Scotland
M2 - Tue Feb 11, 7:22AM CST
US-based Alimera Sciences Inc (Nasdaq:ALIM), a biopharmaceutical company that specialises in the research, development and commercialisation of prescription ophthalmic pharmaceuticals, announced on Monday the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for restricted use within the National Health Service (NHS) Scotland.
Scottish Medicines Consortium Accepts ILUVIEN(R) For National Health Service Scotland
PR Newswire Europe - Mon Feb 10, 8:03AM CST
-- SMC advice follows positive NICE final guidance issued in November 2013
Scottish Medicines Consortium Accepts ILUVIEN® For National Health Service Scotland
PR Newswire - Mon Feb 10, 8:01AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Scottish Medicines Consortium (SMC), after completing its assessment and review of a simple patient access scheme, has accepted ILUVIEN® for restricted use within the National Health Service (NHS) Scotland.
8-K: ALIMERA SCIENCES INC
Edgar Online - Tue Feb 04, 12:47AM CST
ALIM-2014PIPE-Closing8-KDRAFT
Alimera Sciences Closes $37.5 Million Private Placement
PR Newswire - Mon Feb 03, 7:20AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it closed its previously announced private placement of common stock on January 31, 2014. Gross proceeds from the offering were approximately $37.5 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.
Alimera Sciences signs purchase agreement with investors for USD37.5m private placement
M2 - Wed Jan 29, 5:07AM CST
Biopharmaceutical company Alimera Sciences Inc (Nasdaq:ALIM) announced on Tuesday that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately USD37.5m of its common stock in a private placement.
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why AK Steel, Idenix Pharmaceuticals, and Alimera Sciences Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 28, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The three-day losing streak for the broad-based S&P 500 ...
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Tuesday
Synthetic Biologics (SYN) Slumps: Stock Tanks 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:38AM CST
Synthetic Biologics shares fell by over 11%. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future.
Alimera Sciences Announces $37.5 Million Private Placement
PR Newswire - Tue Jan 28, 5:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately $37.5 million of its common stock in a private placement. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 23, 1:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
Great Southern Bancorp, Inc. Reports Preliminary Fourth Quarter and Annual Earnings of $0.62 and $2.42 Per Diluted Common Share, Respectively
PR Newswire - Thu Jan 23, 6:00AM CST
-- Asset Quality: Non-performing assets and potential problem loans, excluding those covered by FDIC loss sharing agreements, totaled $89.3 million at December 31, 2013, a decrease of $32.8 million from December 31, 2012, and a decrease of $8.5 million from September 30, 2013. Non-performing assets, excluding FDIC-covered non-performing assets, at December 31, 2013, were $62.3 million, a decrease of $10.3 million from $72.6 million at December 31, 2012, and a decrease of $887,000 from $63.2 million at September 30, 2013. Non-performing assets were 1.75% of total assets at December 31, 2013, compared to 1.84% at December 31, 2012, and 1.75% at September 30, 2013. Net charge-offs were $2.2 million for the three months ended December 31, 2013, compared to $3.4 million for the three months ended September 30, 2013, and $7.4 million for the three months ended December 31, 2012.
(0)
(0)